AI-powered drug discovery will be trained on natural ingredients to create novel longevity-focused nutraceuticals. New Zealand-based nutraceutical longevity brand SRW …
Continue reading “Insilico and SRW partner to advance longevity science through power of AI”
Novel approach for predicting therapeutic targets using biomedicine-trained large language model discovered 9 potential aging targets. Insilico Medicine, a clinical-stage …
Continue reading “Insilico uses Microsoft’s BioGPT to find targets for aging and disease”
Protein Phase Separation identification could spotlight novel interventions to mitigate Alzheimer’s pathological processes. Recent research demonstrates that protein phase separation …
Generative AI-powered longevity biotech Insilico Medicine has administered the first dose of its anti-fibrotic small molecule inhibitor in a Phase …
Continue reading “Insilico doses first patients in Phase 2 IPF trial”
AI-powered drug discovery biotech moves focus from New York and hopes to raise $200 million, sources claim. Hong Kong-based biotech …
Continue reading “Insilico Medicine files for Hong Kong IPO”
The latest longevity updates from our investment news desk. Kate Tx lands $51 million Series A Gene therapy company Kate …
The latest longevity updates from our investment news desk. NewLimit secures $40m Series A Epigenetic reprogramming startup NewLimit announced $40 …
Continue reading “Longevity investment bulletin: NewLimit, ORA, Insilico Medicine and more”
The latest longevity updates from our investment news desk. AI-discovered drug gets Orphan Drug Designation AI drug discovery company …
Continue reading “Longevity investment bulletin: Mitobridge, Fractyl, Insilico and more”
The latest longevity updates from our investment news desk. Artificial intelligence drug discovery company Insilico Medicine announced the opening …
Continue reading “Longevity investment bulletin: Insilico Medicine, Biophytis, Synartro and more”
